AIRR - ANZCA Institutional Research Repository
Skip navigation
Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMenz, Ben_US
dc.contributor.authorWahba, Men_US
dc.contributor.authorSlattery, Pen_US
dc.contributor.authorThiruvenkatarajan, Ven_US
dc.contributor.authorJohnson, Jen_US
dc.descriptionEthics and governance: This project was approved by the Southern Adelaide Local Health Network Human Research Ethics Committee under reference AUD/19/SAC/76 and site-specific assessment reference AR/19/SAC/76en_US
dc.description.abstractDear Editor, Among many formulations, lidocaine (lignocaine) is available in a transdermal plaster (patch) containing 5% w/w lidocaine (Versatis®, trademark of Grünenthal GmbH used by Seqirus as an authorized user). This formulation is approved for symptomatic treatment of neuropathic pain associated with herpes zoster infection (post-herpetic neuralgia); thus, use of these plasters for other pain conditions is considered off-label. The use of lidocaine 5% plasters (L5%P) in off-label indications has been explored in a limited number of small studies. Currently, L5%P are recommended as a second-line treatment for neuropathic pain in a systematic review by Finnerup et al., limited by weak...en_US
dc.subjectChronic Painen_US
dc.subjectHerpes Zosteren_US
dc.subjectRetrospective Studiesen_US
dc.titleA Retrospective Study of Topical Lidocaine 5% Plasters in Chronic Off-Label Pain Conditionsen_US
dc.typeJournal Articleen_US
dc.identifier.journaltitlePain Medicineen_US
dc.contributor.anzcaSlattery, Pen_US
dc.contributor.anzcaThiruvenkatarajan Ven_US
dc.contributor.anzcaWahba, Men_US
Appears in Collections:Scholarly and Clinical

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.